期刊文献+

1例多发性骨髓瘤治疗期间并发垂体危象 被引量:1

Pituitary crisis in a multiple myeloma patient during treatment
下载PDF
导出
摘要 多发性骨髓瘤(myltiple myeloma,MM)是一种老年病,治疗原则以化疗为主。然而化学治疗相关的不良反应与希恩综合征的临床表现相似,对于无明确产后出血史的老年患者,往往容易造成误诊、漏诊。因此,老年多产的女性,在化疗期间出现顽固性低钠血症及消化道反应时,应考虑希恩综合征的可能,早期明确诊断,及时给予个体化治疗。 Multiple myeloma is common in the older population and is treated mainly with chemotherapy. However, chemotherapy-related side effects imitate the clinical manifestations of Sheehan's syndrome, which leads to misdiagnosis and missed diagnosis, particularly for older patients without a clear history of postpartum hemorrhage. Therefore, when older women with malignant myelomas show refractory hyponatremia and gastrointestinal disorders while under chemotherapy, a diagnosis of Sheehan's syndrome should be considered. The early detection of the disorder will guarantee timely individualized treatment.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第18期1130-1133,共4页 Chinese Journal of Clinical Oncology
关键词 多发性骨髓瘤 希恩综合征个体化治疗 多学科协作 multiple myeloma, Sheehan's syndrome, individualized treatment, multidisciplinary team
  • 相关文献

参考文献16

  • 1侯健.《中国多发性骨髓瘤诊治指南(2011年修订)》诊断部分的解读[J].中华内科杂志,2011,50(10):897-897. 被引量:14
  • 2Dewald GW, Therneau T, Larson D, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma[J]. Blood, 2005, 106(10): 3553-3558.
  • 3Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report[J]. Cancer Res, 2004, 64 (4) :1546-1558.
  • 4Anfuso S, Patrelli TS, Soncini E, et al. A case report of Sheehan's syndrome with acute onset, hyponatremia and severe anemia[J]. Ac- ta Biomed, 2009, 80(1):73-76.
  • 5Errarhay S, Kamaoui I, Bouchikhi C, et al. Sheehan's Syndrome A Case Report and Literature Review[J]. Libyan J Med, 2009, 4(2): 81-82.
  • 6Morani A, Parmar H, Ibrahim M. Teaching neuroimages: sequen- tial MRI of the pituitary in Sheehan syndrome[J]. Neurology, 2012, 78(1) :e3.
  • 7Laway BA, Mir SA, Gojwari T, et al. Selective preservation of ante- rior pituitary functions in patients with Sheehan's syndromeS. Indi- an [J]. Eudocrinol Metab, 2011, 15 Suppl 3:238-241.
  • 8张丽娜,窦京涛.老年垂体前叶功能减退症促性腺激素的变化及意义[J].中国实用内科杂志,2011,31(1):53-55. 被引量:9
  • 9任青娟,贾静,陈少华.腺垂体功能减退症11例误诊分析[J].临床误诊误治,2013,26(2):13-15. 被引量:3
  • 10张如意,董小英.腺垂体功能减退症68例回顾性分析[J].临床荟萃,2010,25(19):1703-1704. 被引量:6

二级参考文献38

共引文献29

同被引文献11

  • 1Richardson, P Sonneveld, MW Schuster, et al. Bortezomib or12 igh-dosedexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005,352(24): 2487-2498.
  • 2Y Takamatsu, K Sunami, H Hata, et al. A phase I study of bortezomib incombination with doxorubicin and intermediate-dose dexamethasone (iPADtherapy) for relapsed or refractory multiple myeloma[J]. Int J Hematol,2010, 92(3): 503-509.
  • 3O'Brien, RM Gaafar, S Popat, et al. Phase II study of first-line bortezomiband cisplatin in malignant pleural mesothelioma and prospective validationof progression free survival rate as a primary end-point for mesotheliomaclinical trials (European Organisation for Research and Treatment ofCancer 08052)[J]. Eur J Cancer, 2013, 49(13): 2815-2822.
  • 4Spiros Fourlanos, P. G. Managing drug-induced hyponatraemia in adults[J].Australian Prescriber, 2003, 26(5): 114-117.
  • 5O'Connor, J Wright, C Moskowitz, et al. Phase II clinical experience withthe novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma[J]. J Clin Oncol, 2005,23(4): 676-684.
  • 6Schelman, Anne M. Traynor, 1 Kyle D. Holen, et al. A phase I study ofvorinostat in combination with bortezomib in patients with advancedmalignancies[J]. Invest New Drugs, 2013, 31(6): 1539-1546.
  • 7LaraJr, Jeff Longmatec, Karen Reckampcet al, et al. Randomized phase IItrial of concurrent versus sequential bortezomib plus docetaxel in advancednon-small-cell lung cancer: a California cancer consortium trial[J]. ClinLung Cancer, 2011, 12(1): 33-37.
  • 8S Brodmann, EG Klaas, R Cathomas, et al. Severe hyponatremia in apatient with mantle cell lymphoma treated with bortezomib: a case reportand review of the literature[J]. Onkologie, 2007, 30(12): 651-654.
  • 9Paydas, S. Hyponatremia is not a rare adverse event in bortezomib-treatedpatients[J]. Chemotherapy, 2011, 57(5): 434-436.
  • 10Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al. Phase I trialof the proteasome inhibitor PS-341 in patients with refractory hematologicmalignancies[J]. J Clin Oncol, 2002, 20(22): 4420-4427.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部